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Abstract
Purpose To determine whether the second eyes (SE) of pa-
tients with bilateral uveitic glaucoma undergoing filtration
surgery have more glaucomatous progression in terms of vi-
sual acuity, visual field (VF) and optic nerve changes com-
pared to the first eyes (FE).
Methods This retrospective study analysed data of 60 eyes
from 30 patients with bilateral uveitic glaucoma who had un-
dergone glaucoma surgery in both eyes on separate occasions.
Humphrey VF progression was assessed using the Progressor
software.
Results The pre-operative IOP between the FE (43.1
± 7.7 mmHg) and SE (40 ± 8.7 mmHg) was not statistically
significant (p = 0.15). IOP reduction was greater in the FE
(64 %) than SE (59.7 %) post-operatively, but the mean IOP
at the final visit in the FE (12.3 ± 3.9 mmHg) and SE (14.5
± 7 mmHg) was not statistically different (p = 0.2). There was
no significant change in mean logMAR readings pre and post-
operatively (0.45 ± 0.6 vs 0.37 ± 0.6, p = 0.4) or between the
FE and SE. The number of SE with CDR > 0.7 increased by
23 % compared to the FE. From 23 available VFs, five SE
(21.7 %) progressed at a median of five locations (range 1–11
points) with a mean local slope reduction of 1.74 ± 0.45 dB/
year (range −2.39 to −1.26), whereas only one FE progressed.
However, there was no significant difference between mean
global rate of progression between the FE (−0.9 ± 1.6 dB/year)
and SE (−0.76 ± 2.1 dB/year, p = 0.17) in the Humphrey VF.
Conclusion In eyes with bilateral uveitic glaucoma requiring
glaucoma surgery, the SEs had more progressed points on VF
and glaucomatous disc progression compared to FEs at the
final visit.
Keywords Uveitic glaucoma . Glaucoma progression .
Filtering surgery . Progressor software
Introduction
Uveitis is bilateral in approximately 75 % of patients, and
about 40 % suffer bilateral intraocular pressure (IOP) eleva-
tion at some point in the course of the disease [1–3]. These
patients often have chronic uveitis and poor vision if left un-
treated [4]. Topical hypotensive agents are able to control the
IOP in 26 % of patients and an additional 62 % required oral
carbonic anhydrase inhibitors (CAI) such as acetazolamide for
additional IOP control [5]. Despite that, about 35 % of adults
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and 60 % of children with uveitic glaucoma inevitably need
glaucoma surgery, either because of oral CAI dependency or
insufficient IOP control while on maximum tolerated medical
therapy (MTMT) [5]. IOP can be severely elevated and insuf-
ficiently controlled with medical therapy, and therefore re-
quires early surgical intervention for IOP control even in the
absence of glaucomatous disc changes [6].
Glaucoma assessment takes into account progression of the
optic disc cupping [7], visual field (VF) [8], peripapillary nerve
bundle atrophy [9] and more recently, retinal nerve fiber layer
thickness [10, 11]. Visual field progression has been derived
almost exclusively from standard automated perimetry (SAP),
and many studies have used only SAP as a primary functional
endpoint [12–14]. The Humphrey VF is one of the most widely
performed tests for diagnosis and monitoring of glaucoma pro-
gression. Progression can be assessed either by event-based
analysis (i.e., whether VF progression has occurred or not)
[15] or trend analysis of the rate of disease progression
[12–14]. Trend analysis with point-wise linear progression
(PLR) uses the rate of loss in decibels per year (dB/year) to
describe localized points that are actively progressing.
In most patients, systemic CAI is stopped in the early post-
operative period to prevent post-operative hypotony and en-
sure maintained aqueous flow through the bleb. With this, the
second eye (SE), which may also be dependent on oral CAI
for IOP control, could develop marked IOP elevation.
Depending on the severity of IOP elevation and the interval
between the first and second surgery, the SE may suffer glau-
coma progression more than the first eye (FE). This study was
therefore performed to determine whether this is in fact the
case in terms of increased cup to disc ratio (CDR), VF pro-
gression, and worsening of visual acuity.
Materials and methods
A retrospective chart review was conducted among patients
who attended the uveitis clinic inMoorfields Eye Hospital from
May 2010 to Nov 2012. Patients with bilateral uveitis who had
undergone bilateral glaucoma surgery, either trabeculectomy or
aqueous shunt device, with or without antimetabolite augmen-
tation, and had been followed up for up to 5 years after surgery
were included. Exclusion criteria were patients with missing
data or inadequate follow-up. The Research Governance
Committee of Moorfields Eye Hospital approved the data col-
lection (protocol LIGS 10201). The study adhered to the tenets
of the Declaration of Helsinki.
The pre-operative data refers to the point when the decision
for surgery was made, i.e., when the patients were on MTMT.
Data collected included age, anatomical uveitis type, glauco-
ma treatment, vertical CDR as reported in the case notes, the
best-corrected visual acuity (BCVA) pre-operatively and an-
nually until 5 years after their respective surgeries, the highest
IOP reading recorded during the entire period before and after
surgery (excluding any IOP elevation within 2 months post-
operatively to account for post-surgical IOP fluctuation) [16],
the pre-operative IOP prior to their respective surgeries and
annually until 5 years post-operatively, the status of the lens at
the time of surgery (either phakic, pseudophakic, or aphakic),
and Humphrey VF data.
The amount of IOP reduction after surgery was described
as the percentage of IOP reduction from the pre-operative IOP
and at 1 year post-operatively. IOP readings were taken using
the Goldmann Applanation Tonometer. The visual acuity was
tested with the Snellen chart using the patients’ spectacles if
worn and then retested with the addition of a pinhole. The best
vision achieved (BCVA) was recorded. Impaired vision was
defined as BCVA between 6/15 and better than 6/60, whereas
poor vision was defined as BCVA poorer than 6/60 according
to the SUN classification [17]. When comparing pre- and
post-operative BCVA, the logarithm of the reciprocal of the
decimal BCVA was used to approximate the logMAR. Eyes
without form vision were classified into one of the low-vision
categories of logMAR conversion: counting fingers = 2.0 and
handmotions = 2.3 [18]. Light perception and no light percep-
tion were excluded, as they were considered not a formed
perception and could not be quantified [19].
Surgical successes were defined as IOP of ≤21 mmHg at
1 year post-operatively, either with glaucoma medications
(qualified success) or without glaucoma medications (com-
plete success) [20, 21]. Post-operative hypotony was defined
as IOP <6 mmHg on two consecutive visits, or one visit re-
quiring intervention. An eye with a vertical CDR of more than
0.7 or reported as having glaucomatous changes such as focal
notching, rim pallor, or excavation of the rim is considered to
have glaucomatous disc changes [22].
VFs were done every 4–6 months, depending on the neces-
sity as judged by the attending ophthalmologist. Progression
of glaucomatous VF loss was assessed using the Progressor
software (version 3.3; Medisoft Inc, London, United
Kingdom). The software calculates point-wise linear regres-
sion (PLR) analysis and provides local slopes of progression
(in dB/year) for each of the 59 locations in the VF as well as
globally, and its level of significance (p values). A Gaussian
filter was applied to reduce measurement variability without
additional testing or exclusion of noisy tests to allow inclusion
of all available VF tests irrespective of reliability criteria [23].
A test point was considered progressing if the slope of sensi-
tivity over time exceeded 1 dB/year (with p < 0.01). For edge
points, a stricter slope criterion of >2 dB loss/year (also with
p < 0.01) was used [24].
Data were analysed using Stata version 10 (Intercooled)
(StataCorp, College Station, TX, USA). All categorical vari-
ables were compared using chi-square test and a paired t-test
was used to compare means for normally distributed data. The
Mann–Whitney test was used to compare means of non-
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parametric data. For data counts of less than 5 in any sub-
groups, the Fisher exact test was used to compare proportions.
Survival analysis and Kaplan–Meier graphs were plotted to
assess the annual probability of surgical success in the first
5 years post-operatively. A linear mixed model analysis was
used to assess the annual rate of visual loss and progression of
the vertical CDR in the first 5 years post-operatively. Cox’s
regression analysis was performed to assess the risk factors for
surgical failure, and multivariate logistic regression analysis
was used to determine the risk factors for bleb failure in
trabeculectomy. Results are reported as mean and standard
deviation unless stated otherwise.
Results
A total of 43 patients with uveitis underwent bilateral glauco-
ma surgery. Thirteen patients were excluded because of miss-
ing data (n = 9), inadequate follow-up period (n = 3) and co-
existence of retinitis pigmentosa (n = 1). Therefore, 60 eyes of
30 patients were included in the analysis.
The male to female ratio was 1:1.3. The mean age was
39 years (range 7–66 years), with seven children and 23
adults. The FE was the right in 16 patients and left in 14
patients. Fourteen patients (46.7 %) had anterior uveitis, eight
patients (26.7 %) had intermediate uveitis, and a further eight
patients (26.7 %) had posterior/panuveitis. The mean follow-
up period was 12.0 ± 9.4 years (range 3–42 years).
Glaucoma surgery was performed on the FE at a median
duration of 6.5 years (range 1–36 years) after the diagnosis of
uveitis. The first operated eye was the eye with more poorly
controlled IOP. The timing for the SE surgery depended on the
IOP control while on medical treatment. In SEs with poor IOP
control, or borderline IOP control with a glaucomatous disc,
surgery is performed earlier. Themean interval between surgery
of the FE and SEwas 30.3 months (range: 0.25 to 180months).
Nine SEs (30 %) had surgery within 6 months after the FE
surgery, and 21 SEs (70 %) had it after 6 months. Forty-one
eyes (68.3 %) had trabeculectomy, and 19 eyes (31.7 %) had
aqueous shunt implantation (three Molteno and 16 Baerveldt
devices) with or without antimetabolite augmentation.
When operating the FE, ten of 30 SE (33 %) had no
glaucomatous disc changes, with a mean IOP of 32 and
30 mmHg in the FE and SE respectively. Some of the SEs were
controlled medically until the decision for the SE surgery was
made. Both FE and SE received approximately the same mean
number of drops (3.2 and 3.1 in the FE and SE respectively).
Pre-operative treatment and the indications for surgery
The mean number of pre-operative topical classes of glauco-
ma medications was 3.1 ± 0.88 drops. Twenty-seven eyes
(45 %) had four medications, 21 eyes (35 %) had three
medications, nine eyes (15 %) had two medications, and three
eyes (5 %) had one type of medication pre-operatively.
Patients who had less than four medications could not tolerate
other medications due to their side-effects. Twenty-one of 30
patients (70 %) received oral acetazolamide before surgery of
the FE, which was stopped immediately after the FE surgery.
We compared the highest pre-operative IOP in the FE and
SE to determine whether cessation of oral acetazolamide had
led to severe IOP elevation in the SE.We found no statistically
significant difference in the mean highest pre-operative IOP
between the FE (43.2 ± 7.8 mmHg, range 28–56 mmHg) and
SE (39.8 ± 8.7 mmHg, range 26–65 mmHg), p = 0.15. The
indications for glaucoma surgery were: (1) dependency on
oral acetazolamide in nine eyes (15 %), four of them SE, (2)
advanced glaucomatous disc cupping at borderline IOP con-
trol (IOP 19–21 mmHg) on MTMT in 11 eyes (18.3 %), and
(3) insufficient IOP control on MTMT with or without
glaucomatous cupping in the remaining 40 eyes (66.7 %).
There was no difference in the distribution of FE and SEs
according to IOP, CDR, and number of glaucoma drops pre-
operatively (Table 1).
The Kaplan–Meier graph in Fig. 1 illustrates the cumula-
tive probability of normal IOP in the SE after cessation of oral
acetazolamide following the first surgery against time. IOP
elevation was observed in 43 % of SEs within the first year
after the FE surgery, 18.4 % in the second year, and 12.2 % in
the third, fourth, and fifth year respectively.
Post-operative outcome
Post-operative outcome in patients who received oral
acetazolamide before the FE surgery
Out of 21 patients who received acetazolamide, seven SEs
(16.7 %) vs four FEs (9.5 %) showed progression in CDR,
while four SEs (9.5 %) and two FEs (4.7 %) had VF progres-
sion after a mean duration of 9 ± 5.7 years postoperatively. The
mean pre-operative highest IOP in the SEs (36 ± 8.7 mmHg)
was also higher than the FE s(32 ± 7.8 mmHg) although it did
not reach statistical significance (p = 0.06).
In SEs which had surgery > 6 months after FE surgery, IOP
in the SE could be controlledmedically for the first fewmonths.
Of the 21 SEs which had surgery > 6 months after FE surgery,
three eyes (14 %) had disc progression and four eyes (19 %)
had VF progression, as opposed to one of the nine SEs (11 %)
which had surgery < 6 months after FE surgery developed disc
and VF progression. However, because of the small number of
eyes affected, statistical significance was not achieved.
Visual acuity
While there was no eye with light perception vision pre-oper-
atively, two FEs had final VA of light perception. The
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underlying causes were advanced GON alone and a dense
cataract with advanced GON in each eye.
To estimate the mean rate of change in BCVA within the
first 5 postoperative years, a linear mixed model of mean
logMAR was fitted, with the postoperative years as the inde-
pendent variable and the FE and SE nested within patients.
The estimated mean rate of progression was 0.02 logMAR per
year and this was not found to be statistically significant (co-
efficient estimate 0.02, p = 0.38, 95 % CI −0.026 to 0.07). The
estimated mean rate of progression in the FE was 0.05
logMAR per year (coefficient estimate 0.052, p = 0.143,
95 % CI: −0.018 to 0.122) and in the SE was −0.02
logMAR per year (coefficient estimate −0.02, p = 0.473,
95 %CI: −0.076 to 0.035).
In general, there was neither a significant difference in the
median logMAR BCVA pre-operatively (0.3) and at the final
visit (0.2, p = 0.4), nor was there any significant difference in
the distribution of FEs and SEs with impaired and poor vision
pre-operatively. However, at the final visit, there were signif-
icantly more FEs with poor vision and more SEs with im-
paired vision, p = 0.02 (Table 1).
Of the eyes with final BCVA poorer than 6/60 (n = 6), in
only one eye was this exclusively due to advanced GON. The
rest was due to hypotony maculopathy following glaucoma
surgery and related to low IOP, choroidal neovascular mem-
brane at the macula, combination of aphakia, band keratopa-
thy and advanced GON, and a dense cataract (n = 1
respectively).
Table 1 Comparison of study outcomes between the first and second eye before surgery and at the final visit
Study outcome Before surgery At final visit
FE, n = 30 SE, n = 30 P FE, n = 30 SE, n = 30 P
BCVA in logMAR, median 0.3 0.2 0.43a 0.2 0.3 0.47a
BCVA, no. of eyes (%)
≥6/15 8 (26.7) 6 (20.0) 4 (13.3) 13(43.3)
≥ 6/60 1 (3.3) 4 (13.3) 0.47b 5 (16.7) 1 (3.3) 0.02b
CDR ≥0.7, no. of eyes (%) 19 (65.5) 13 (44.83) 0.12c 19 (65.52) 16 (55.2) 0.42c
CDR, mean (SD) 0.67 (0.24) 0.54 (0.25) 0.06a 0.67 0.63 0.4
IOPe, mean (SD) 35.2 (12.2) 31.4 (9.4) 0.2d 12.3 ± 4 14.5 ± 7 0.2d
Number of classes of glaucoma drugs, mean (SD) 3.23 (0.9) 3.1 (0.9) 0.6a 1.8 2.3 0.3a
BCVA best-corrected visual acuity, FE first eye, SE second eye, CDR cup to disc ratio, SD standard deviation, IOP intraocular pressure
aMann–Whitney test
b Fisher’s exact test
c Chi square test
d paired t-test
e the IOP before surgery refers to the IOP on maximum tolerated medical therapy
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Fig. 1 Kaplan–Meier graph
illustrating the cumulative
probability of normal IOP in the
second eye after oral
acetazolamide was stopped
following surgery in the first eye.
IOP elevation was defined as
IOP > 22 mmHg
Graefes Arch Clin Exp Ophthalmol
Optic disc appearance
Two eyes were excluded in the analysis of optic disc appear-
ance because the discs were obscured by a dense cataract and
band keratopathy (one eye each) at the final visit. Among eyes
where the optic disc was visible (n = 58), 32 eyes (55.2 %) had
CDR > 0.7 pre-operatively. This number increased by three
eyes (9.4 % increment) at the last visit, and this increase oc-
curred in the SEs (3/13 eyes, 23.1 % increment). A linear
mixed model analysis revealed no significant CDR progres-
sion between the FEs and SEs within the first 5 years post-
operatively (mean CDR 0.6, coefficient estimate 0.006,
p = 0.443, 95 % CI −0.01 to 0.02).
To cater for variability in reporting CDR between observers
in the clinic, progression of the CDR was considered present
when the ratio was reported as increasing by 0.2 or more.With
this definition, five eyes progressed within 5 years post-oper-
atively, which were 2 FEs and 3 SEs. Although it appeared
from the Kaplan–Meier graph in Fig. 2 that the rate of CDR
progression is higher in the SEs, a log rank test revealed no
significant difference in the overall CDR progression between
the FEs and SEs, p = 0.34. The survival rates of CDR progres-
sion in the FEs and SEs at 1, 2, and 5 years were 100 and
96.1 %, 95.8 and 91.6 %, 89 and 68.7 % respectively (Fig. 2).
Intraocular pressure, IOP-lowering treatment and surgical
success
The mean IOP in all eyes reduced from 33.2 ± 10.7 mmHg
pre-operatively to 14.0 ± 4.7 mmHg at 1 year post-operatively,
resulting in a mean decline of 19.5 mmHg after 1 year (57.8 %
reduction, p < 0.001). This reductionwasmore in the FE (from
a mean of 35.2 ± 12.2 to 12.6 ± 4.5 mmHg, 64.2 % reduction),
than the SE (from a mean of 31.4 ± 9.2 to 15.25 ± 7.8 mmHg,
51.4 % reduction) at 1 year post-operatively. However, the
mean IOP in the FE and SE at 1 year postoperatively
(p = 0.23) and at the final visit (12.7 ± 5.4 vs 14.1
± 7.0 mmHg in the FE and SE respectively, p = 0.4) was not
statistically significant.
Figure 3 demonstrates the distribution of pre- and post-
operative IOP in the FE and SE. The bisecting line showed
that the IOP was lower after surgery in the FE but was not
significantly so in the SE. The regression line for the FE
showed that a higher pre-operative IOP is associated with a
higher IOP at 1 year post-op (correlation coefficient, r = 0.53,
p = 0.01), whereas this positive correlation was not seen in the
SE (correlation coefficient, r = −0.06, p = 0.78).
The overall qualified success at 1 year post-operatively was
92.5 %, and complete success was 73 %. There was no sig-
nificant difference in the survival rates of qualified success
between the FE and SE, p = 0.86. The survival rates of qual-
ified success of the FE and SE were 96.4 and 93 % at 1 year,
87.6 and 88.2 % at 2 years, 83 and 81 % at 5 years postoper-
atively (Fig. 4). There was also no significant difference in the
survival rate between SEs that had surgery within 6 months or
after 6 months post FE surgery. In eyes with equally high IOP
before the first surgery, bilateral surgery was planned to be
performed within a short period between the two eyes.
Cox regression analysis was performed to evaluate the risk
factors for surgical failure (IOP >21 mmHg) within the first 5
post-operative years. Factors included were the patients’ age
at the time of surgery, the number of pre-operative glaucoma
medications, and the state of the lens at the time of surgery.
The type of glaucoma surgery (whether trabeculectomy or
aqueous shunt) was not a significant factor (Hazard ratio,
HR 1.3, p = 0.7) and therefore was not included. After
adjusting for the other factors, the risk of failure reduced by
37.7 % with every 10-year increase in age (adjusted
HR = 0.623, p = 0.04, 95 % CI: 0.39–0.99). The number of
pre-operative glaucoma drops and the state of the lens at the
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Fig. 2 Kaplan–Meier graph
showing the difference in
cumulative survival risk of CDR
progression between the first eye
(FE) and second eye (SE)
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time of surgery was not a significant factor for surgical failure
in this model.
At the final visit, 34 eyes (53.1 %) had IOP ≤ 12 mmHg
and four eyes (6.25 %) had IOP ≥ 21 mmHg. A total of 28
eyes (43.7 %) were on hypotensive agents, six eyes were on
one, seven eyes on two, ten eyes on three, and five eyes on
four agents. Twelve out of 41 trabeculectomy eyes (29.3 %)
required a secondary procedure, either a revision of
trabeculectomy, needling, or implantation of aqueous shunt
with or without 5-Fluorouracil. Hypotony occurred in 12 eyes
(18.7 %), intravitreous haemorrhage occurred in one eye, and
another eye had to undergo reformation of anterior chamber
with viscoelastic agent. A multivariate logistic regression
analysis revealed that aphakic or pseudophakic eyes undergo-
ing trabeculectomy were 4 times more likely to undergo a
secondary procedure compared to phakic eyes after adjusting
for age (OR 4.5, p = 0.04, 95 % confidence interval 1.1–19.6).
The number of pre-operative glaucoma drops was not found to
be a significant risk factor, and was therefore not included in
this model.
Visual field analysis
Of the 30 patients, 23 had sufficient VF tests for analysis, with
a mean of 6.5 tests per patient (range: three to 15 tests). Ten of
36 eyes (28 %) with VFs had less than five VF tests per-
formed. This was because some eyes had very poor vision to
perform a meaningful VF, and the decision for surgery has to
bemade based on IOP control and disc changes. Overall, there
was no significant difference between the mean number of
progressed points pre-operatively (0.17 points, range 0–3)
and at the final visit (0.63 points, range 0–11), p = 0.28. The
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SE showed progression in five patients (21.7 %), the FE
progressed in one patient (4.3 %), and no progression oc-
curred in either eye in the remaining 17 patients (74 %) at
the final visit. In the SEs that progressed, the median number
of progressed points was five locations (range 1 to 11 points),
with a mean local slope reduction of −1.74 ± 0.45 dB/year
(range −2.39 to −1.26). There was no significant difference
in the mean reduction of the global slope between the FE and
SE postoperatively (−0.75 ± 0.6 and −0.9 ± 0.4 dB/year re-
spectively, p = 0.83).
A multivariate linear regression was performed to deter-
mine the risk factors for local and global slope progression.
The factors examined were the occurrence of hypotony, the
highest IOP reading after surgery, the time from the first to
second surgery, and the duration of follow-up. We found no
association between the local and global slope progression
with the risk factors, possibly because of the small number
of eyes that progressed.
However, when examining the risk factors for increased
number of progressed points, hypotony was found to be asso-
ciated with increased number of progressed points by 0.7
points (regression coefficient 0.68, 95 % CI 0.01–1.34,
p = 0.046) after adjusting for the highest IOP and duration of
follow-up.
Discussion
This study was performed to answer the question of whether
cessation of oral acetazolamide following glaucoma surgery
of the FE may be associated with severe IOP elevation and
hence more glaucoma progression in the SE compared to the
FE. It involved relatively young patients (mean age 39
± 22.1 years) who had developed elevated IOP as a complica-
tion of chronic uveitis or corticosteroid treatment. There was a
wide range of follow-up, which may influence some of the
progression seen in these patients.
In 70 % of SEs, raised IOP requiring glaucoma surgery
occurred 6 months or later after the first surgery, suggesting
that majority of the second surgery can be delayed until the FE
has stabilized. Cessation of acetazolamide did not result in a
higher pre-operative maximum IOP in the SE compared to the
FE. This might indicate that with acetazolamide withdrawal
following the first surgery, the SE IOP did not go higher but
reverted back to the level before the FE surgery.
Our mean pre-operat ive IOP while on MTMT
(33.2 mmHg) was comparable to the 33.7 mmHg mean pre-
operative IOP in a study on long-term outcome of
trabeculectomy in 101 uveitic eyes [16], although our patients
had more pre-operative drops (3.1 vs 2.86 drops), and more
patients were prescribed oral acetazolamide (70 % vs 66.3 %)
when compared to those in their study. This could indicate that
medical treatment may only reduce the IOP up to a certain
level and that surgery in this group of patients is inevitable.
Nearly 67 % of eyes in our study had insufficient IOP control
(IOP >21 mmHg) prior to surgery whilst on MTMT, compa-
rable to the 60% reported success of non-surgical treatment in
children with uveitis [5].
Unlike primary glaucomas, surgery is performed in uveitis
for IOP control, even in the absence of glaucomatous optic
neuropathy [6]. This is because the IOP may continue to in-
crease to an unacceptable level despite MTMT because of per-
sistent steroid therapy required to maintain uveitis inactivity.
Nevertheless, progressive glaucomatous damage could be seen
post-operatively, more in the SE than the FE, and occurring
both anatomically (increase in eyes with CDR > 0.7) and func-
tionally (increase in number of progressed points on VF test).
In general, glaucoma surgery in our study resulted in a
mean IOP reduction by 57.8 %, slightly lower than that re-
ported in other studies involving uveitic eyes (59 %) [21] but
higher in those of non-uveitic eyes (40 %) [13]. However, this
difference is due to the different definitions of pre-operative
IOP used. The first study used the highest IOP reading, where-
as the second study took the average of all IOP readings pre-
operatively.We defined pre-operative IOP as the IOP while on
MTMT to illustrate that any further IOP reduction following
surgery was from the effect of surgery alone and not from any
contribution from medical therapy. Although mean IOP re-
duction was more in the FE (64.2 %) than SE (51.4 %), the
mean IOP at 1 year post-operatively and at the final visit was
not statistically different between the two eyes. The difference
in the period between the first and second surgery did not have
any effect on the surgical success in the SE (Fig. 4).
Furthermore, the difference with regard to VF and CDR
changes in the FE and SE is only moderate considering that
the delay between the FE and SE surgery is quite long.
Although greater IOP reduction can often be achieved with
surgery when medical therapy is insufficient, surgical inter-
vention may not be enough to cease VF progression, as IOP
fluctuation has also been identified as a risk factor for VF
progression, especially in advanced glaucoma and low mean
IOP [25–27]. Postoperative hypotony occurred in 16 % of our
patients (20 % of eyes), slightly lower than the figure quoted
by previous studies on uveitic eyes (19.4 %) [21]. A multivar-
iate linear regression was unable to demonstrate any associa-
tion between the global and local slope progression of the VF
with either the occurrence of hypotony or the maximum IOP
reading after surgery, probably because of the small number of
eyes that progressed. However, hypotony was the only signif-
icant risk factor found to be associated with an increased num-
ber of progressing points.
Qualified success in our study at 1 year post-operatively
was 92.5 % and complete success was 73 %, comparable to a
study by Chawla et al. who reported 90.3 and 71 % of qual-
ified and complete success respectively at 1 year post
trabeculectomy on adult uveitic patients [21]. Although there
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was no difference in the survival rates of qualified success
between the FE and SE, the rates steadily decreased in both
eyes within the first 5 years. As a result, glaucoma progression
can be seen as a steady decrease in the survival rates of CDR
progression, more in the SE, although this does not translate
into significant VF progression both in the local and global
slope of the point-wise linear regression.
While the use of multiple hypotensive agents pre-operatively
and the state of the lens (aphakia/pseudophakia) were found to
be responsible for a higher failure rate in non-uveitic glaucoma
surgery [27], we found no association between them and the
odds of surgical success in uveitis. It could be that success of
glaucoma surgery in uveitis is influenced by many other factors
different to those in non-uveitic glaucomas. On the other hand,
we found younger patients more likely to develop surgical fail-
ure, agreeing with previous studies [28], possibly because of
their inclination to mount scar tissue formation compared to
the elderly. However, because surgical success only takes into
account the IOP at any given time, other bleb-saving procedures
were not demonstrated as surgical failures.
The drawbacks of VF progression analysis in our cohort of
patients were that the number and interval of VF between
patients were unequal, which may fail to demonstrate the true
VF progression. Analysis with the Progressor software in our
study allowed for inclusion of all available VFs by using the
Gaussian filter. Even so, we found no significant difference in
the mean number of progressed points pre-operatively and at
the final visit. Additionally, there were no progressed points in
about three quarter of patients. In eyes that did progress, the
global rate of progression was more in the SE than the FE
post-operatively albeit an insignificant difference. The SE
progressed in five patients, as opposed to one patient with
FE progression. The mean number of progressed points in
our study (0.63 points) was far more from the one reported
by Fulgar et al. (0.07 progressed points) in a study involving
28 patients with a mixture of POAG, angle-closure glaucoma,
and pseduexfoliation glaucoma [13]. Again, this higher figure
of progressed VF points in our cohort of patients could be
attributed to other pathologies related to uveitis, such as retinal
and macular scars, apart from the severity of GON. Even if we
have achieved comparable IOP reduction with previous stud-
ies, our patients still eventually lose vision.
Consistent with recommendation by previous reports,
trabeculectomy was the primary surgical procedure in nearly
70 % of eyes in our study. Traditionally, trabeculectomy with
an antifibrotic agents has been the initial procedure in patients
with glaucoma who have failed medical and/or laser therapy,
and aqueous shunt only comes into play when trabeculectomy
fails or in the presence of other factors such as aphakic and
pseudophakic patients, JIA-related uveitis, or other risk factors
for trabeculectomy failure [6, 29–31]. Therefore, the success rate
of aqueous shunt would be expected to be limited because of the
refractory nature of the patients’ eyes following one or more
failed filtering surgeries. However, there has been increasing
evidence in recent years that aqueous shunt may be the initial
procedure of choice over trabeculectomy because of the dreaded
complications of trabeculectomy such as bleb-related infections,
bleb leaks and bleb dysthesia [32]. Some studies have reported
comparable success rate of trabeculectomy with mitomycin C in
uveitic glaucoma and POAG [33]. Almost 30 % of
trabeculectomized eyes in our study required a secondary pro-
cedure, either revision of trabeculectomy or aqueous shunt im-
plantation after a failed trabeculectomy.
The limitations of this study are mainly because of its ret-
rospective design and relatively small sample size, although
large for the type of patients. Estimation of the CDR is highly
variable between different observers in the clinic; and optic
disc stereo-photograph, which is the gold standard for estimat-
ing progression, was not available in all patients. VFs were
also performed at irregular intervals, making standardization
of VF progression difficult. However, the findings of this
study are still relevant to illustrate the clinical outcome in
patients with bilateral uveitis and raised IOP. This group of
patients with recalcitrant IOP elevation does show glaucoma
progression in certain aspects, even though sufficient IOP
control was attained. The SE scored lower in a few aspects,
namely structurally (more SEs with CDR > 0.7 at the final
visit) and to a lesser extent, functionally (more progressed
points and higher progression rate in those points). But be-
cause of its small sample size and wide range of follow-up
duration, statistical significance was not achieved. A well-
designed long-term prospective study with sequential optic
disc photographs would be able to determine optic disc pro-
gression better. The findings in this study may suggest that in
some eyes, earlier glaucoma surgery may probably improve
the prognosis of the second eye.
In conclusion, the SE scored lower than the FE as there
were more SEs with impaired vision, more progressed points
on Humphrey VF, and more eyes with CDR ≥ 0.7 at the final
visit. This is especially so in patients who have received oral
acetazolamide before the FE surgery. Cessation of oral acet-
azolamide causes glaucomatous progression in approximately
double the number of SEs compared to the FEs, although pre-
operative IOP was not significantly different between the two
groups of eyes. This is clinically significant, as the final visual
outcome may be influenced by both glaucoma and uveitis
activity. However, there was no difference in the final
logMAR BCVA, the final IOP, and the final global progres-
sion on VF. Even if we have achieved comparable IOP reduc-
tion with previous studies, our patients still eventually lose
vision from glaucoma and the effects of uveitis.
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